Men Xin, Su Mengyang, Ma Jun, Mou Yueyang, Dai Penggao, Chen Chao, Cheng Xi An
School of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Microbiology Institute of Shaanxi, Xi'an, Shaanxi, China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211004916. doi: 10.1177/15330338211004916.
Tamoxifen (TAM) is the eminent first-line drug for endocrine therapy of hormone receptor positive premenopausal breast cancer and reduces the risk of recurrence by ∼50%. However, many patients developed TAM resistance and their diseases recurred. Our previous study on transcriptome profile of TAM resistant breast cancer cells revealed that the TMEM47 is one of the most significantly differentially expressed genes. The mechanism of how TMEM47 is involved in TAM resistance was not known.
We constructed a mammal breast cancer cell line, in which TMEM47 was stably overexpressed (TMEM47-OE/MCF-7), to further verify the role of TMEM47 in TAM resistance. siRNA targeting TMEM47 was transfected into TAMR / MCF-7 cells by Liposome. TMEM47 expression was validated on mRNA and protein level by qRT-PCR and western blotting. We tested the cytotoxicity of TAM in the cells. Apoptosis was detected by flow cytometry.
Compared to the MCF7 cells, TMEM47 mRNA was significantly up regulated more than 6 folds in the TAMR/MCF7 cells and so its protein. TMEM47 expression level in TMEM47-OE/MCF-7 was similar as in the TAMR/MCF-7 cells. The 50% inhibitory concentration (IC50) value (mean ± SD) of TAM in MCF-7, TAMR/MCF-7 and TMEM47-OE/MCF-7 cells was 1.58 ± 0.19, 2.74 ± 0.24 and 3.12 ± 0.32 µγ/mL, respectively. The apoptosis rates of TAMR/MCF-7 and TMEM47-OE/MCF-7 cell lines were significantly lower than that of MCF-7 cells. After 24 and 48 hours TAM treatments, cell viability was significantly inhibitied in TMEM47 knockdown TAMR/MCF7 cells (P < 0.01). Consistant with the decreased cell viability, the apoptosis rate in TMEM47 knockdown TAMR/MCF-7 cells was significantly increased.
Our results suggest that overexpression of TMEM47 in MCF-7 cells acquired TAM resistance to those cells, and knockdown of TMEM47 in TAMR/MCF-7 cells reversed their resistance to TAM. TMEM47 might confer TAM resistance on MCF-7 cells through the inhibition of apoptosis.
他莫昔芬(TAM)是激素受体阳性绝经前乳腺癌内分泌治疗的重要一线药物,可将复发风险降低约50%。然而,许多患者出现了TAM耐药,疾病复发。我们之前对TAM耐药乳腺癌细胞转录组图谱的研究表明,TMEM47是差异表达最显著的基因之一。TMEM47如何参与TAM耐药的机制尚不清楚。
我们构建了一种哺乳动物乳腺癌细胞系,其中TMEM47稳定过表达(TMEM47-OE/MCF-7),以进一步验证TMEM47在TAM耐药中的作用。通过脂质体将靶向TMEM47的siRNA转染到TAMR / MCF-7细胞中。通过qRT-PCR和蛋白质印迹在mRNA和蛋白质水平验证TMEM47的表达。我们检测了TAM在细胞中的细胞毒性。通过流式细胞术检测细胞凋亡。
与MCF7细胞相比,TAMR/MCF7细胞中TMEM47 mRNA显著上调超过6倍,其蛋白质也是如此。TMEM47-OE/MCF-7中TMEM47的表达水平与TAMR/MCF-7细胞中的相似。TAM在MCF-7、TAMR/MCF-7和TMEM47-OE/MCF-7细胞中的50%抑制浓度(IC50)值(平均值±标准差)分别为1.58±0.19、2.74±0.24和3.12±0.32 µγ/mL。TAMR/MCF-7和TMEM47-OE/MCF-7细胞系的凋亡率显著低于MCF-7细胞。在TAM处理24和48小时后,TMEM47敲低的TAMR/MCF7细胞中的细胞活力显著受到抑制(P < 0.01)。与细胞活力降低一致,TMEM47敲低的TAMR/MCF-7细胞中的凋亡率显著增加。
我们的结果表明,MCF-7细胞中TMEM47的过表达使这些细胞获得了TAM耐药性,而TAMR/MCF-7细胞中TMEM47的敲低逆转了它们对TAM的耐药性。TMEM47可能通过抑制细胞凋亡赋予MCF-7细胞TAM耐药性。